• Je něco špatně v tomto záznamu ?

Application of Oil-in-Water Cannabidiol Emulsion for the Treatment of Rheumatoid Arthritis

P. Jelínek, J. Roušarová, P. Ryšánek, M. Ježková, T. Havlůjová, J. Pozniak, P. Kozlík, T. Křížek, T. Kučera, M. Šíma, O. Slanař, M. Šoóš

. 2024 ; 9 (1) : 147-159. [pub] 20221104

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007465

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease with unknown cause. It mainly affects joints and, without proper treatment, negatively impacts their movement, causes painful deformities, and reduces the patients' quality of life. Current treatment options consist of various types of disease-modifying antirheumatic drugs (DMARDs), however 20-30% of patients are partially resistant to them. Therefore, development of new drugs is necessary. Possible option are compounds exhibiting their action via endocannabinoid system, which plays an important role in pain and inflammation modulation. One such compound - cannabidiol (CBD) has already been shown to attenuate synovitis in animal model of RA in in vivo studies. However, it has low bioavailability due to its low water solubility and lipophilicity. This issue can be addressed by preparation of a lipid containing formulation targeting lymphatic system, another route of absorption in the body. Materials and Methods: CBD-containing emulsion was prepared by high-shear homogenization and its droplet size distribution was analysed by optical microscopy. The relative oral bioavailability compared to oil solution as well as total availability of CBD were assessed in a cross-over study in rats and absorption of CBD via lymphatic system was observed. The effect of CBD on the animal model of RA was determined. Results: Compared to oil solution, the emulsion exhibited higher absolute oral bioavailability. Significant lymphatic transport of CBD was observed in all formulations and the concentrations in lymph were calculated. The therapeutic effect of CBD on RA was confirmed as an improvement in clinical symptoms as well as morphological signs of disease activity were observed during the study. Conclusion: In this work, we prepared a simple stable emulsion formulation, determined the pharmacokinetic parameters of CBD and calculated its absolute bioavailability in rats. Moreover, we successfully tested the pharmaceutical application of such a formulation and demonstrated the positive effect of CBD in an animal model of RA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007465
003      
CZ-PrNML
005      
20240423160002.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1089/can.2022.0176 $2 doi
035    __
$a (PubMed)36342775
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jelínek, Petr $u Department of Chemical Engineering, Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Czech Republic
245    10
$a Application of Oil-in-Water Cannabidiol Emulsion for the Treatment of Rheumatoid Arthritis / $c P. Jelínek, J. Roušarová, P. Ryšánek, M. Ježková, T. Havlůjová, J. Pozniak, P. Kozlík, T. Křížek, T. Kučera, M. Šíma, O. Slanař, M. Šoóš
520    9_
$a Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease with unknown cause. It mainly affects joints and, without proper treatment, negatively impacts their movement, causes painful deformities, and reduces the patients' quality of life. Current treatment options consist of various types of disease-modifying antirheumatic drugs (DMARDs), however 20-30% of patients are partially resistant to them. Therefore, development of new drugs is necessary. Possible option are compounds exhibiting their action via endocannabinoid system, which plays an important role in pain and inflammation modulation. One such compound - cannabidiol (CBD) has already been shown to attenuate synovitis in animal model of RA in in vivo studies. However, it has low bioavailability due to its low water solubility and lipophilicity. This issue can be addressed by preparation of a lipid containing formulation targeting lymphatic system, another route of absorption in the body. Materials and Methods: CBD-containing emulsion was prepared by high-shear homogenization and its droplet size distribution was analysed by optical microscopy. The relative oral bioavailability compared to oil solution as well as total availability of CBD were assessed in a cross-over study in rats and absorption of CBD via lymphatic system was observed. The effect of CBD on the animal model of RA was determined. Results: Compared to oil solution, the emulsion exhibited higher absolute oral bioavailability. Significant lymphatic transport of CBD was observed in all formulations and the concentrations in lymph were calculated. The therapeutic effect of CBD on RA was confirmed as an improvement in clinical symptoms as well as morphological signs of disease activity were observed during the study. Conclusion: In this work, we prepared a simple stable emulsion formulation, determined the pharmacokinetic parameters of CBD and calculated its absolute bioavailability in rats. Moreover, we successfully tested the pharmaceutical application of such a formulation and demonstrated the positive effect of CBD in an animal model of RA.
650    _2
$a zvířata $7 D000818
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a aplikace orální $7 D000284
650    12
$a revmatoidní artritida $x farmakoterapie $7 D001172
650    12
$a kanabidiol $x farmakologie $x chemie $7 D002185
650    _2
$a klinické křížové studie $7 D018592
650    _2
$a emulze $7 D004655
650    _2
$a bolest $x farmakoterapie $7 D010146
650    _2
$a kvalita života $7 D011788
650    _2
$a voda $7 D014867
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Roušarová, Jaroslava $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Ryšánek, Pavel $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Ježková, Martina $u Department of Chemical Engineering, Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Czech Republic
700    1_
$a Havlůjová, Tereza $u Department of Chemical Engineering, Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Czech Republic
700    1_
$a Pozniak, Jiří $u Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
700    1_
$a Kozlík, Petr $u Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Křížek, Tomáš $u Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Kučera, Tomáš $u Institute of Histology and Embryology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Šíma, Martin $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/000000026541738X $7 xx0222901
700    1_
$a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Šoóš, Miroslav $u Department of Chemical Engineering, Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Czech Republic $1 https://orcid.org/0000000297427160
773    0_
$w MED00209151 $t Cannabis and cannabinoid research $x 2378-8763 $g Roč. 9, č. 1 (2024), s. 147-159
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36342775 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155959 $b ABA008
999    __
$a ok $b bmc $g 2081453 $s 1217232
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 9 $c 1 $d 147-159 $e 20221104 $i 2378-8763 $m Cannabis and cannabinoid research $n Cannabis Cannabinoid Res $x MED00209151
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace